美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Global Partners Lp

51.66

-0.2353-0.45%

成交量：5,866.00

成交额：30.36万

市值：17.52亿

市盈率：16.52

高：52.20

开：52.20

低：51.51

收：51.90

数据加载中...

总览公司新闻公告

昊帆生物股价小幅回落世卫组织将发布GLP-1减肥新指南

港股异动 | 联邦制药(03933)涨超8% 机构指UBT251具备GLP-1药物减重效果BIC潜力

GLP-1这次真的“卷到头了”

沃尔玛：即将到来的SNAP削减、GLP-1和其他不利因素使其估值难以接受

美股研究社

大摩：Hims(HIMS.US)目标价40美元存18%下行空间，GLP-1诉讼拉锯战成最大变数

世界模型也被泼冷水了？邢波等人揭开五大“硬伤”，提出新范式

【大行评级｜招银国际：上调信达生物目标价至102.95港元看好其丰富的创新管线】招银国际发表研究报告指出，信达生物旗下IBI363(PD-1/IL-2)具显著的存活益处和巨大潜力，有望成为重磅级下一代免疫疗法，尤其适用于免疫耐受性和冷肿瘤，目前正在进行第三阶段临床试验。除IBI363外，信达生物正打造强大的下一代免疫肿瘤(IO)药物和抗体药物偶联物(ADC)的产品组合，并在IO-ADC联合治疗策略领域处于前沿，是未来肿瘤药物开发的关键趋势。此外，信达生物亦正开发多款创新免疫肿瘤药物，包括PD-1/IL-12、PD-L1/CD40，以及多个靶向GPRC5D/BCMA/CD3、DLL3/CD3和CLDN18.2/CD3的靶向T细胞衔接器(TCE)等。另外，公司最近推出玛仕度肽(Mazdutide)，是中国首款国产双标靶GLP-1肥胖症治疗药物，标志着其非肿瘤药物组合中的重大里程碑。招银国际对信达生物丰富的创新管线以及其在全球的潜力持乐观态度，认为公司有望在今年实现EBITDA收支平衡。该行将信达生物目标价从94.74港元上调至102.95港元，维持“买入”评级。

平台上演GLP-1药物“三强争霸”，中国首款GLP-1减重药物于美团线上首发

从“减重效率”到“减重质量”，GLP-1“战争”下半场逻辑剧变

歌礼制药-B(01672)：小分子口服GLP-1R激动剂ASC30美国13周IIa期研究完成首批肥胖或超重受试者给药

港股概念追踪 | 首款国产GLP-1双靶点减肥药获批上市国内多家药企布局减肥药赛道(附概念股)

首款国产GLP-1双靶点减肥药获批上市如何与进口减肥药差异化竞争

速递｜一夜股价腰斩！Altimmune GLP-1新药疗效令投资人失望

GLP1减重宝典

首个国产GLP-1减重创新药获批在即，非官方售价已曝光

速递｜全球首款！针对疼痛，礼来启动GLP-1三靶点药物 III 期临床

GLP1减重宝典

礼来成GLP-1最大赢家

速递｜安进下调GLP-1药物III期研究剂量：降低剂量以限制副作用

GLP1减重宝典

礼来口服GLP-1药物Orforglipron安全性仍存争议

平安证券：GLP-1RA未来市场前景广阔建议关注减脂增肌赛道等投资机遇

全球首个偏向型 GLP-1减重药中国Ⅲ期临床数据公布

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/GLP/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","market":"US","secType":"STK","nameCN":"Global Partners Lp","latestPrice":51.6647,"timestamp":1753287403374,"preClose":51.9,"halted":0,"volume":5866,"delay":0,"floatShares":29460749,"shares":33904637,"eps":3.127877,"marketStatus":"交易中","change":-0.2353,"latestTime":"07-23 12:24:04 EDT","open":52.2,"high":52.2,"low":51.51,"amount":303552.47748,"amplitude":0.013295,"askPrice":51.92,"askSize":100,"bidPrice":50.98,"bidSize":200,"shortable":3,"etf":0,"ttmEps":3.127877,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1753300800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1127966400000,"exchange":"NYSE","adjPreClose":51.9,"dividendRate":0.056809,"postHourTrading":{"tag":"盘后","latestPrice":51.9,"preClose":51.9,"latestTime":"19:42 EDT","volume":1444,"amount":74911.2,"timestamp":1753227743439},"volumeRatio":0.378731,"impliedVol":0.2397,"impliedVolPercentile":0.168},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","floatShares":29460749,"roa":"4.67%","roe":"18.09%","lyrEps":2.44604,"volumeRatio":0.378731,"shares":33904637,"dividePrice":2.935,"high":52.2,"amplitude":0.013295,"preClose":51.9,"low":51.51,"week52Low":37.0034,"pbRate":"2.83","psRate":"0.10","week52High":60,"institutionHeld":0.4838,"latestPrice":51.6647,"committee":0.333333,"eps":3.127877,"divideRate":0.056809,"volume":5866,"delay":0,"ttmEps":3.127877,"open":52.2,"prevYearClose":46.55,"prevWeekClose":51.54,"prevMonthClose":52.73,"prevQuarterClose":52.73,"fiveDayClose":51.38,"twentyDayClose":53.21,"sixtyDayClose":51.87},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2553525742","title":"昊帆生物股价小幅回落 世卫组织将发布GLP-1减肥新指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2553525742","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553525742?lang=zh_cn&edition=fundamental","pubTime":"2025-07-23 00:24","pubTimestamp":1753201441,"startTime":"0","endTime":"0","summary":"截至2025年7月22日15时，昊帆生物股价报55.37元，较前一交易日下跌0.74%。当日成交量为28927手，成交金额达1.61亿元。昊帆生物所属板块包括生物制品、CRO等领域。世界卫生组织计划于2025年9月发布基于GLP-1疗法的成人肥胖症治疗新指南。该指南将明确GLP-1受体激动剂的临床应用标准，标志着世卫组织首次正式推荐使用减肥药物治疗肥胖症。在相关产业链中，昊帆生物被列为值得关注的企业之一。2025年7月22日，昊帆生物主力资金净流入74.15万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/23002451904873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4590","GLP","BK0229","301393","BK4144"],"gpt_icon":0},{"id":"2553286746","title":"港股异动 | 联邦制药(03933)涨超8% 机构指UBT251具备GLP-1药物减重效果BIC潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2553286746","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553286746?lang=zh_cn&edition=fundamental","pubTime":"2025-07-22 11:54","pubTimestamp":1753156499,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，联邦制药涨超8%，截至发稿，涨8.04%，报16.66港元，成交额4.67亿港元。消息面上，联邦制药近期公布，拟配售1.56亿股新股，每股配售价14.16港元，较上一日收盘价折让约7.93%；配售股份相当于扩大后的已发行股本约7.91%。国泰海通证券指出，三靶点注射剂UBT251具备BIC潜力，与诺和诺德达成重磅授权。该行认为，UBT251具备GLP-1药物减重效果BIC潜力，与全球龙头诺和诺德的共同开发下，有望充分兑现药物价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1320430.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4590","BK4144","03933","BK1191","GLP"],"gpt_icon":0},{"id":"2551902631","title":"GLP-1这次真的“卷到头了”","url":"https://stock-news.laohu8.com/highlight/detail?id=2551902631","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551902631?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 07:31","pubTimestamp":1752622290,"startTime":"0","endTime":"0","summary":"全球超过30亿超重或肥胖人群构成的庞大市场，让GLP-1类药物成为医药行业最炙手可热的赛道。“卷”不动了GLP-1市场的“内卷”已触及天花板，市场饱和度提升与销售增速下滑的迹象日益显著。根据2025年初数据显示，目前全球处于临床试验阶段的GLP-1相关管线高达179个，仅中国申报临床的GLP-1类新药就已超过了50个。GLP-1从来不缺乏争议，但争议的焦点早已从“谁能颠覆胰岛素”变成了“谁还能留在牌桌”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716074053a6ac01cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716074053a6ac01cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1571399168.USD","IE00BFTCPJ56.SGD","LU1057294990.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","NVO","LU0289739699.SGD","LU0058720904.USD","MRK","LU1061106388.HKD","GLP","LU0320765992.SGD","LU0868494617.USD","BK4585","LU0109394709.USD","BK4534","BK4533","LU2468319806.SGD","LU1983299246.USD","LU0122379950.USD","LU2242646821.SGD","BK4581","IE0002141913.USD","LU0889565916.HKD","LU2112291526.USD","SG9999001440.SGD","LU2242652126.USD","BK4590","LU1023059063.AUD","BK4599","LLY","LU2089984988.USD","BK4566","BK4588","IE00BJJMRZ35.SGD","BK4144","BK4139","AMGN","IE0009355771.USD","IE00BJT1NW94.SGD"],"gpt_icon":1},{"id":"2550377196","title":"沃尔玛：即将到来的SNAP削减、GLP-1和其他不利因素使其估值难以接受","url":"https://stock-news.laohu8.com/highlight/detail?id=2550377196","media":"美股研究社","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550377196?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 19:25","pubTimestamp":1752060346,"startTime":"0","endTime":"0","summary":"但一些特定的催化剂，包括SNAP福利的减少和GLP-1的使用，可能会损害沃尔玛的收入和利润。沃尔玛是SNAP福利支出的最大受益者，约占SNAP支出总额的四分之一。有子女的家庭通常使用 SNAP12 个月，而老年人和单身人士通常使用 SNAP 超过 50 个月。尽管如此，考虑到沃尔玛每年近7000亿美元的营收，虽然其会感受到SNAP削减的影响，但直接的财务影响可能并不大。考虑到SNAP福利削减、通货膨胀、关税以及潜在的消费者行为变化等不利因素，这个估值尤其令人难以接受。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709202105a69f6d8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709202105a69f6d8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1280957306.USD","LU1116320901.HKD","LU0949170772.SGD","LU2125154935.USD","LU0289960550.SGD","LU1988902786.USD","BK4534","LU1066051225.USD","LU0175139822.USD","LU2430703095.HKD","LU2461242641.AUD","BK4581","LU1064131342.USD","LU1116320737.USD","LU2750360641.GBP","BK4532","LU0310799852.SGD","LU1003077747.HKD","LU1585245621.USD","BK4588","LU2361044949.HKD","LU2361045086.USD","BK4077","LU0661504455.SGD","LU1035773651.USD","LU0957791311.USD","BK4144","LU0211328371.USD","LU2264538146.SGD","BK4554","LU0553294199.USD","LU2430703178.SGD","LU2471134952.CNY","LU1066053197.SGD","BK4550","GLP","BK4533","LU0256863902.USD","LU1814569148.SGD","LU1066051498.USD","LU0545039389.USD","LU1069347547.HKD","WMT","LU1815333072.USD","IE0034235188.USD","LU0096362180.USD","LU2125154778.USD","LU2361044865.SGD","LU2505996509.AUD"],"gpt_icon":0},{"id":"2550686726","title":"大摩：Hims(HIMS.US)目标价40美元存18%下行空间，GLP-1诉讼拉锯战成最大变数","url":"https://stock-news.laohu8.com/highlight/detail?id=2550686726","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550686726?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 15:57","pubTimestamp":1752047831,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，大摩维持对Hims & Hers Health Inc“持股观望”评级，目标价40美元，较当前股价存在约18%的下行空间。大摩指出，Hims当前市值约为98.92亿美元，52周股价区间为13.48至72.98美元。大摩强调，目前礼来和诺和诺德尚未对配药公司提起专利侵权诉讼，但专家普遍认为，专利侵权诉讼未来仍有可能发生。而下行风险则包括GLP-1药品短缺问题持续、市场份额被竞争对手蚕食，以及监管政策变化对制造和远程医疗业务的冲击。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HIMS","GLP"],"gpt_icon":1},{"id":"2550682661","title":"世界模型也被泼冷水了？邢波等人揭开五大“硬伤”，提出新范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2550682661","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550682661?lang=zh_cn&edition=fundamental","pubTime":"2025-07-09 15:41","pubTimestamp":1752046860,"startTime":"0","endTime":"0","summary":"研究者表示，PAN 世界模型的详细信息及结果会很快在另一篇论文中展示。它将世界模型作为一个“模拟器”，让一个独立的智能体模型在其中探索并学习 。PAN 世界模型基于对现有世界模型框架的批评，作者得出了关于通用世界模型设计原则。作为通用生成模型，PAN 能够模拟现实世界中可操作的可能性，使智能体能够进行有目的的推理。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-07-09/doc-infewkcm4729021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4138","LU0456854461.SGD","BK4588","BK4590","CMU","LU0266512127.USD","RL","LU0368265418.SGD","MPC","LU0300736062.USD","IE00BSNM7G36.USD","BK4144","BK4202","LU0300736492.USD","LU0170899867.USD","LU0122376428.USD","GLP","LU0788109394.HKD","LU0006061336.USD","BK4585"],"gpt_icon":0},{"id":"2549596714","title":"【大行评级｜招银国际：上调信达生物目标价至102.95港元 看好其丰富的创新管线】招银国际发表研究报告指出，信达生物旗下IBI363(PD-1/IL-2)具显著的存活益处和巨大潜力，有望成为重磅级下一代免疫疗法，尤其适用于免疫耐受性和冷肿瘤，目前正在进行第三阶段临床试验。除IBI363外，信达生物正打造强大的下一代免疫肿瘤(IO)药物和抗体药物偶联物(ADC)的产品组合，并在IO-ADC联合治疗策略领域处于前沿，是未来肿瘤药物开发的关键趋势。此外，信达生物亦正开发多款创新免疫肿瘤药物，包括PD-1/IL-12、PD-L1/CD40，以及多个靶向GPRC5D/BCMA/CD3、DLL3/CD3和CLDN18.2/CD3的靶向T细胞衔接器(TCE)等。另外，公司最近推出玛仕度肽(Mazdutide)，是中国首款国产双标靶GLP-1肥胖症治疗药物，标志着其非肿瘤药物组合中的重大里程碑。 招银国际对信达生物丰富的创新管线以及其在全球的潜力持乐观态度，认为公司有望在今年实现EBITDA收支平衡。该行将信达生物目标价从94.74港元上调至102.95港元，维持“买入”评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2549596714","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549596714?lang=zh_cn&edition=fundamental","pubTime":"2025-07-08 11:50","pubTimestamp":1751946620,"startTime":"0","endTime":"0","summary":"招银国际发表研究报告指出，信达生物旗下IBI363具显著的存活益处和巨大潜力，有望成为重磅级下一代免疫疗法，尤其适用于免疫耐受性和冷肿瘤，目前正在进行第三阶段临床试验。招银国际对信达生物丰富的创新管线以及其在全球的潜力持乐观态度，认为公司有望在今年实现EBITDA收支平衡。该行将信达生物目标价从94.74港元上调至102.95港元，维持“买入”评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/08115051548552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","01801","PD","ADC","GLP"],"gpt_icon":0},{"id":"2548361404","title":"平台上演GLP-1药物“三强争霸”，中国首款GLP-1减重药物于美团线上首发","url":"https://stock-news.laohu8.com/highlight/detail?id=2548361404","media":"广州日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548361404?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 17:08","pubTimestamp":1751620103,"startTime":"0","endTime":"0","summary":"美团又一次成为GLP-1减重药物的首发平台。7月3日，刚刚获批的减重创新药物玛仕度肽注射液（商品名：信尔美?）在美团医药健康旗下美团自营大药房首发上线。对此，专家提醒：购买、用药仍需遵医嘱或在专业药师指导下进行。据悉，这是继口服版司美格鲁肽和替尔泊肽之后，美团又一次承接GLP-1药物的全网独家首发，三款减重药物也将于美团平台内上演“三强争霸”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507043448631272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","LU1328277881.USD","LU0463099449.HKD","LU0797268264.HKD","LU0588546209.SGD","LU1880383440.USD","METmain","LU1868838027.USD","GLP","BK1589","LU0348735423.USD","LU1105468828.SGD","LU0143863784.USD","LU0499858602.USD","LU0011963245.USD","LU0979878070.USD","LU1102505762.USD","MPNGY","IE0034224299.USD","LU0871576103.HKD","LU0823040885.USD","BK1521","LU1794554557.SGD","LU0509642566.USD","LU0251144936.SGD","LU0149721374.USD","LU0700851271.USD","LU0737861699.HKD","LU0417516902.SGD","BK1610","LU0072913022.USD","LU0531971595.HKD","03690","IE0008369823.USD","LU0326948709.USD","LU1993786604.SGD","IE00B29SXG58.USD","LU0326950275.SGD","LU0819121731.USD","LU0049853897.USD","LU0605514214.HKD","BK1583","LU0541502299.USD","HMTD.SI","LU1880383366.USD","LU0594300179.USD","LU0449515922.USD","LU1770034418.SGD","LU0577902298.EUR","LU0456827905.SGD"],"gpt_icon":1},{"id":"2548735332","title":"从“减重效率”到“减重质量”，GLP-1“战争”下半场逻辑剧变","url":"https://stock-news.laohu8.com/highlight/detail?id=2548735332","media":"钛媒体APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548735332?lang=zh_cn&edition=fundamental","pubTime":"2025-07-04 11:21","pubTimestamp":1751599276,"startTime":"0","endTime":"0","summary":"文 | 医曜司美格鲁肽与替尔泊肽均成为“药王级”产品，似乎GLP-1已然兑现了市场对它的期待。两大行业巨头礼来与诺和诺德，看似稳坐云端宝座，实则危机四伏，各路豪强对GLP-1下半场虎视眈眈。GLP-1争夺战并未结束，即将开启的下半场或将出现更大规模的拼杀。这一结果使CagriSema成为首个在III期临床试验中实现超过20%减重效果的双靶点代谢药物组合，被业界视为GLP-1发展的关键里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704112548a72de8ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704112548a72de8ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1551013425.SGD","LU0323591593.USD","GLP","LU2491050154.USD","LU0238689110.USD","LU2456880835.USD","SGXZ99366536.SGD","LU1093756325.SGD","LU1917777945.USD","LU0256863902.USD","IE0004445239.USD","LU2461242641.AUD","LU0471298694.HKD","LU0256863811.USD","IE00BJJMRZ35.SGD","LU1868837300.USD","LU0289739699.SGD","LU0316494557.USD","LU0385154629.USD","SG9999001176.SGD","LU0417517546.SGD","LU1069344957.HKD","SGXZ81514606.USD","BK4534","LU1720051108.HKD","LU1093756168.USD","SG9999015945.SGD","SG9999015952.SGD","LU2462157665.USD","LU2361044865.SGD","LU0203201768.USD","LU0823416689.USD","LU1232071149.USD","LU2237443622.USD","LU2750360997.AUD","LU0058720904.USD","BK4533","BK4007","BK4588","IE00B4R5TH58.HKD","LU0689472784.USD","LU0122379950.USD","LU2324357040.USD","LLY","LU0203202063.USD","SG9999014880.SGD","LU0943347566.SGD","LU0320765059.SGD","LU0006306889.USD","LU1035775433.USD"],"gpt_icon":1},{"id":"2548451028","title":"歌礼制药-B(01672)：小分子口服GLP-1R激动剂ASC30美国13周IIa期研究完成首批肥胖或超重受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2548451028","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548451028?lang=zh_cn&edition=fundamental","pubTime":"2025-07-03 07:08","pubTimestamp":1751497709,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，小分子口服GLP-1受体激动剂ASC30治疗肥胖症的美国13周IIa期研究已完成首批受试者给药，受试者为肥胖人群或伴有至少一种体重相关合并症的超重人群。由歌礼自主研发的ASC30是首款也是唯一一款既可每日一次口服也可每月一次皮下注射的用于治疗肥胖症的在研小分子GLP-1R偏向激动剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4144","BK4590","GLP","BK1574","BK1515","BK1161","01672","BK1191","01477"],"gpt_icon":0},{"id":"2547033197","title":"港股概念追踪 | 首款国产GLP-1双靶点减肥药获批上市 国内多家药企布局减肥药赛道(附概念股)","url":"https://stock-news.laohu8.com/highlight/detail?id=2547033197","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547033197?lang=zh_cn&edition=fundamental","pubTime":"2025-06-30 07:23","pubTimestamp":1751239421,"startTime":"0","endTime":"0","summary":"据悉，中国已获批了四款GLP-1减肥药上市，分别是利拉鲁肽、贝那鲁肽、司美格鲁肽及替尔泊肽，前两款药物属于短效制剂，生产厂家是国产企业；后两款是长效制剂，为进口药物。恒瑞医药的GLP-1/GIP双靶点药物HRS-7535在Ⅲ期临床试验中取得了显著的减重效果，减重效果达18%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1311461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4614","BK1583","YANG","LU2328871848.SGD","BK1589","HSCEI","BK1161","GLP","01801","02105","BK1515","HSTECH","LU1969619763.USD","BK1574","LU2488822045.USD","BK4590","01672","BK4144"],"gpt_icon":1},{"id":"2546747731","title":"首款国产GLP-1双靶点减肥药获批上市 如何与进口减肥药差异化竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2546747731","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546747731?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 23:10","pubTimestamp":1751037048,"startTime":"0","endTime":"0","summary":"【首款国产GLP-1双靶点减肥药获批上市 如何与进口减肥药差异化竞争】6月27日，国家药品监督管理局批准信达生物申报的1类创新药玛仕度肽注射液上市，适用于在控制饮食和增加体力活动基础上对成人患者的长期体重控制，初始体重指数（BMI）为：BMI≥28 kg/m2（肥胖）；或BMI≥24 kg/m2（超重），并伴有至少一种体重相关的合并症（例如高血糖、高血压、血脂异常、脂肪肝、阻塞性睡眠呼吸暂停综合征等）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506273442770443.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506273442770443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4144","GLP","BK4590"],"gpt_icon":0},{"id":"2546713920","title":"速递｜一夜股价腰斩！Altimmune GLP-1新药疗效令投资人失望","url":"https://stock-news.laohu8.com/highlight/detail?id=2546713920","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546713920?lang=zh_cn&edition=fundamental","pubTime":"2025-06-27 16:36","pubTimestamp":1751013387,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队Altimmune, Inc.公司今日公布了其候选药物pemvidutide在代谢相关脂肪性肝炎治疗中IMPACT 2b期临床试验的积极初步结果。然而，其疗效令投资人失望，股价一夜之间腰斩。治疗期间的退出率较低，仅9%的受试者提前终止治疗。治疗组在ELF和VCTE等非侵入性纤维化评估及ALT炎症指标方面均显著优于安慰剂。因不良反应停药率在两个治疗组中分别为0.0%和1.2%，安慰剂组为2.4%。未报告与研究药物相关的严重不良事件或心律失常。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627165430a720734f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627165430a720734f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1878469433.USD","BK4139","ALT","BK4599","BK4590","BK4144","GLP"],"gpt_icon":1},{"id":"2546745734","title":"首个国产GLP-1减重创新药获批在即，非官方售价已曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2546745734","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546745734?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 22:46","pubTimestamp":1750949161,"startTime":"0","endTime":"0","summary":"第一财经记者从多方了解到，由信达生物开发的首个国产GLP-1减重创新药玛仕度肽注射液减重适应症预计最快将于本周获批。截至6月26日收盘，信达生物（1801.HK）股价下跌约5%。信达生物此前公开表示，玛仕度肽减重和降糖两项适应症都有望于今年年内获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202506263441555398.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202506263441555398.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4590","BK4144","BK1161","BK1574","GLP","06978"],"gpt_icon":0},{"id":"2546827407","title":"速递｜全球首款！针对疼痛，礼来启动GLP-1三靶点药物 III 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2546827407","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546827407?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 11:35","pubTimestamp":1750908925,"startTime":"0","endTime":"0","summary":"据 Insight 数据库，这是全球首次开展 GLP1R/GIPR/GCGR 三激动剂用于疼痛治疗的 III 期研究。TRIUMPH-7 为一项随机、双盲、安慰剂对照的国际多中心研究，预计将在 2025 年 6 月启动，2027 年 9 月完成。试验计划入组 586 名受试者，随机分组接受每周一次的 Retatrutide 或安慰剂注射，治疗周期为 80 周。次要终点则涵盖疼痛缓解人数、体重减轻达标人数等多项指标。目前该药正处于多个适应症的 III 期临床阶段，涵盖肥胖、2 型糖尿病、心血管事件二级预防以及阻塞性睡眠呼吸暂停等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626114125a71e1f64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626114125a71e1f64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BJJMRZ35.SGD","LU2106854487.HKD","SGXZ99366536.SGD","LU0079474960.USD","LU2237443895.HKD","LU1232071149.USD","LU1093756168.USD","LU1868836591.USD","LU0256863902.USD","LU2552382058.USD","LU2746668461.USD","III","LU0114720955.EUR","LU0471298694.HKD","LU1983299246.USD","LU0882574139.USD","LU1720051017.SGD","LU2456880835.USD","LU1061106388.HKD","LU2491050071.SGD","LU2236285917.USD","LU2237443978.SGD","IE0002141913.USD","LU2471134879.HKD","LLY","LU1989771016.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","SG9999018865.SGD","LU0238689110.USD","LU2471134952.CNY","BK4581","LU1917777945.USD","LU0640476718.USD","LU0109394709.USD","SG9999015986.USD","LU1064131342.USD","LU0689472784.USD","LU1093756325.SGD","LU2461242641.AUD","LU1814569148.SGD","LU2552382215.SGD","SG9999013999.USD","LU0198837287.USD","LU0316494557.USD","LU0106261372.USD","GLP","LU1069344957.HKD","LU2602419157.SGD","IE00BK4W5L77.USD"],"gpt_icon":1},{"id":"2546227962","title":"礼来成GLP-1最大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2546227962","media":"医药魔方","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546227962?lang=zh_cn&edition=fundamental","pubTime":"2025-06-26 08:20","pubTimestamp":1750897235,"startTime":"0","endTime":"0","summary":"报告显示，到2030年，全球处方药总销售额预计将增长至1.756万亿美元，届时GLP-1药物销售额将占处方药总销售额的9%。GLP-1热潮的最大者受益者非礼来莫属，EvaluatePharma认为“礼来在这场竞赛中的霸主地位已经很明显了”。在EvaluatePharma的畅想中，礼来也将成为2030年营收最高的药企，增速一骑绝尘。但未来5年，抗肿瘤药物的发展势头不如GLP-1药物和免疫炎症药物，帕博利珠单抗、纳武利尤单抗、达雷妥尤单抗等重磅产品将陆续失去专利保护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626082402a71dd87e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626082402a71dd87e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1917777945.USD","LU1366192091.USD","IE00BJLML261.HKD","LU2237443549.SGD","LU2023250504.SGD","IE00B2B36J28.USD","LU0058720904.USD","SG9999014906.USD","LU2417539215.USD","LU2746668461.USD","LU1551013425.SGD","LU1267930730.SGD","LU2237443622.USD","LU0320765059.SGD","LU0114720955.EUR","LU0889565916.HKD","LU0097036916.USD","LU0820561818.USD","SG9999014914.USD","LLY","LU1061106388.HKD","LU2237438978.USD","BK4588","LU2361045086.USD","LU2602419157.SGD","LU2237443465.HKD","LU0471298777.SGD","SG9999015986.USD","BK4144","LU2264538146.SGD","LU2471134879.HKD","LU2237443382.USD","LU0316494557.USD","LU0823416689.USD","LU0106261372.USD","GLP","BK4007","LU2324357040.USD","LU0238689110.USD","LU1720051108.HKD","LU2063271972.USD","SG9999017495.SGD","LU2360106947.USD","LU0122379950.USD","LU0456855351.SGD","LU0640476718.USD","SG9999015952.SGD","LU0094547139.USD","SGXZ51526630.SGD","IE00BK4W5M84.HKD"],"gpt_icon":1},{"id":"2546261925","title":"速递｜安进下调GLP-1药物III期研究剂量：降低剂量以限制副作用","url":"https://stock-news.laohu8.com/highlight/detail?id=2546261925","media":"GLP1减重宝典","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546261925?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 11:20","pubTimestamp":1750821603,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队根据周一公布的一项新的中期试验结果，安进公司实验性肥胖症治疗药物MariTide必须从低剂量开始治疗，以减少呕吐等副作用。此前，安进报告称，在一项为期一年的2期临床试验中，MariTide帮助患者减重高达20%。其副作用与其他 GLP-1 类药物一致。相比之下，诺和诺德公司的 GLP-1 药物 Wegovy 在后期研究中的呕吐发生率为 24%。安进公司的数据还显示，接受逐渐增加 MariTide 剂量的患者因胃肠道副作用而停止治疗的可能性较小。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625112810a71c41b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625112810a71c41b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","IE00BJT1NW94.SGD","BK4588","BK4139","BK4534","IE00BFTCPJ56.SGD","LU1983299246.USD","LU1571399168.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","IE0002141913.USD","LU0320765992.SGD","IE0009355771.USD","BK4533","LU2468319806.SGD","BK4566","BK4134","IE00B2B36J28.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","LU0868494617.USD","LU2242652126.USD","BK4581","LU1061106388.HKD","LU2242646821.SGD","LU0058720904.USD","LU2089984988.USD","III","LU2112291526.USD","GLP","SG9999001440.SGD","LU0109394709.USD","AMGN","LU1057294990.SGD","BK4599","LU0289739699.SGD","BK4590","LU0122379950.USD","BK4144"],"gpt_icon":0},{"id":"2546265827","title":"礼来口服GLP-1药物Orforglipron安全性仍存争议","url":"https://stock-news.laohu8.com/highlight/detail?id=2546265827","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546265827?lang=zh_cn&edition=fundamental","pubTime":"2025-06-25 07:55","pubTimestamp":1750809300,"startTime":"0","endTime":"0","summary":"礼来口服GLP-1药物Orforglipron在ADA年会展示减重效果，但胃肠道副作用引发争议，其安全性待确认。该药正处于减肥适应症关键试验阶段，市场期待其减重数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625102135978dba60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625102135978dba60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0689472784.USD","LU0708995401.HKD","LU0640476718.USD","LU0061475181.USD","LU1814569148.SGD","LU2471134796.USD","LU0058720904.USD","LU0109391861.USD","GLP","LU1712237335.SGD","LU1232071149.USD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU2106854487.HKD","LU1069344957.HKD","IE00BK4W5M84.HKD","LU1868837136.USD","LU1868837300.USD","LU2471134952.CNY","LU0943347566.SGD","LU1917777945.USD","LU2471134879.HKD","SGXZ31699556.SGD","LU1720051108.HKD","LU2237443895.HKD","SG9999018865.SGD","LU0889565916.HKD","LU2236285917.USD","LU2471134523.USD","SGXZ57979304.SGD","LU0471298694.HKD","LU0122379950.USD","SG9999014914.USD","LU2491049909.HKD","SG9999014906.USD","SGXZ51526630.SGD","SG9999015952.SGD","LU0109394709.USD","LU2456880835.USD","SG9999015978.USD","LLY","LU2265009873.SGD","IE00BK4W5L77.USD","LU2237443622.USD","SG9999014880.SGD","LU0096364046.USD","SG9999015986.USD","IE00BJJMRZ35.SGD","LU1868836591.USD","LU0354030438.USD"],"gpt_icon":0},{"id":"2545445405","title":"平安证券：GLP-1RA未来市场前景广阔 建议关注减脂增肌赛道等投资机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2545445405","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545445405?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 15:44","pubTimestamp":1750751070,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，平安证券发布研报称，GLP-1RA在降糖和减重领域表现强劲，随着新适应症的不断获批和临床数据的积累，GLP-1类药物在糖尿病、肥胖症以及可能的其他治疗领域中的应用前景将更加广阔，市场规模也将进一步扩大。该行建议关注“减脂增肌赛道”、“超长效制剂”以及“口服制剂”国内药企相关投资机遇。为解决GLP-1药物导致的肌肉流失问题，国内外药企纷纷布局减脂增肌赛道。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308900.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4144","GLP","161027","BK4590"],"gpt_icon":0},{"id":"2545474092","title":"全球首个偏向型 GLP-1减重药中国Ⅲ期临床数据公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2545474092","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545474092?lang=zh_cn&edition=fundamental","pubTime":"2025-06-24 13:45","pubTimestamp":1750743900,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 6月24日，界面新闻记者从先为达处获悉，该公司公布了其自主研发的全球首个偏向型GLP-1减重药物埃诺格鲁肽（Ecnoglutide，曾用名伊诺格鲁肽）注射液Ⅲ期临床试验（SLIMMER）研究成果。研究成果显示，相比于安慰剂，埃诺格鲁肽治疗疗效显著且安全优势明显，减重幅度高达15.1%，创下目前中国人群Ⅲ期研究48周最高记录。（界面新闻记者 黄华）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/t/2025-06-24/doc-infccywn9157045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4144","GLP","BK4590"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":126,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLP\",params:#limit:5,,,undefined,":[{"date":"2025-05-09","symbol":"GLP","amount":0.745,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-09","defaultRemindTime":1746797400000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-15","payableDate":"2025-05-09","currency":"USD","dateTimestamp":1746763200000,"payDate":"2025-05-15"},{"market":"US","date":"2025-05-08","symbol":"GLP","fiscalQuarterEnding":"2025/03","expectedEps":-0.03,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":0.36},{"market":"US","date":"2025-02-28","symbol":"GLP","fiscalQuarterEnding":"2024/12","expectedEps":0.24,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740718800000,"reportTimeType":"pre","actualEps":0.52},{"date":"2025-02-10","symbol":"GLP","amount":0.74,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-10","defaultRemindTime":1739197800000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-14","payableDate":"2025-02-10","currency":"USD","dateTimestamp":1739163600000,"payDate":"2025-02-14"},{"date":"2024-11-08","symbol":"GLP","amount":0.73,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-08","defaultRemindTime":1731076200000,"name":"全球合伙","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-14","payableDate":"2024-11-08","currency":"USD","dateTimestamp":1731042000000,"payDate":"2024-11-14"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLP\",market:\"US\",,,undefined,":[{"executeDate":"2015-08-03","recordDate":"2015-08-05","paymentDate":"2015-08-14","value":0.6925,"currency":"USD"},{"executeDate":"2015-11-02","recordDate":"2015-11-04","paymentDate":"2015-11-13","value":0.6975,"currency":"USD"},{"executeDate":"2016-02-08","recordDate":"2016-02-10","paymentDate":"2016-02-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-05-04","recordDate":"2016-05-06","paymentDate":"2016-05-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-08-04","recordDate":"2016-08-08","paymentDate":"2016-08-12","value":0.4625,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1741060800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GLP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GLP","date":"2025-07-22","current":15.021507,"percent":0.745586,"low":2.771386,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"high":29.34912,"avg":10.714701,"sd":6.333109,"marketCap":1732865997},"quantilePoints":[{"date":"2020-07-24","current":10.543265,"twenty":6.333279,"median":8.291955,"eighty":11.303569,"marketCap":325997749},{"date":"2020-07-31","current":11.800516,"twenty":6.334178,"median":8.348313,"eighty":11.303569,"marketCap":364871958},{"date":"2020-08-07","current":4.73435,"twenty":6.333279,"median":8.360564,"eighty":11.32112,"marketCap":438154667},{"date":"2020-08-14","current":5.006778,"twenty":6.3117,"median":8.298445,"eighty":11.316433,"marketCap":463367300},{"date":"2020-08-21","current":4.712262,"twenty":6.299659,"median":8.287054,"eighty":11.303569,"marketCap":436110400},{"date":"2020-08-28","current":4.701217,"twenty":6.299607,"median":8.274802,"eighty":11.298552,"marketCap":435088266},{"date":"2020-09-04","current":4.542915,"twenty":6.2824,"median":8.213544,"eighty":11.285346,"marketCap":420437682},{"date":"2020-09-11","current":4.749076,"twenty":6.27606,"median":8.174338,"eighty":11.274368,"marketCap":439517512},{"date":"2020-09-18","current":4.815342,"twenty":6.275736,"median":8.086126,"eighty":11.269162,"marketCap":445650315},{"date":"2020-09-25","current":4.73435,"twenty":6.258044,"median":8.00583,"eighty":11.265698,"marketCap":438154667},{"date":"2020-10-02","current":4.933149,"twenty":6.250305,"median":7.971673,"eighty":11.259925,"marketCap":456553075},{"date":"2020-10-09","current":5.360198,"twenty":6.244429,"median":7.94745,"eighty":11.2525,"marketCap":496075580},{"date":"2020-10-16","current":5.26448,"twenty":6.239772,"median":7.932539,"eighty":11.247278,"marketCap":487217087},{"date":"2020-10-23","current":5.271843,"twenty":6.23717,"median":7.912422,"eighty":11.243223,"marketCap":487898510},{"date":"2020-10-30","current":5.338109,"twenty":6.227089,"median":7.896854,"eighty":11.239367,"marketCap":494031312},{"date":"2020-11-06","current":5.459545,"twenty":6.22179,"median":7.88907,"eighty":11.21862,"marketCap":522855188},{"date":"2020-11-13","current":5.670214,"twenty":6.203808,"median":7.87934,"eighty":11.19873,"marketCap":543030764},{"date":"2020-11-20","current":5.877313,"twenty":6.196135,"median":7.85015,"eighty":11.194013,"marketCap":562864382},{"date":"2020-11-27","current":6.170107,"twenty":6.185826,"median":7.85015,"eighty":11.189536,"marketCap":590905013},{"date":"2020-12-04","current":6.109406,"twenty":6.168749,"median":7.838474,"eighty":11.169685,"marketCap":585091712},{"date":"2020-12-11","current":6.416483,"twenty":6.167844,"median":7.834582,"eighty":11.145422,"marketCap":614500179},{"date":"2020-12-18","current":6.230809,"twenty":6.167844,"median":7.828744,"eighty":11.130907,"marketCap":596718315},{"date":"2020-12-24","current":6.048705,"twenty":6.167844,"median":7.82096,"eighty":11.115597,"marketCap":579278410},{"date":"2020-12-31","current":5.934444,"twenty":6.167844,"median":7.817068,"eighty":11.101741,"marketCap":568335725},{"date":"2021-01-08","current":6.062987,"twenty":6.149862,"median":7.795662,"eighty":11.084422,"marketCap":580646246},{"date":"2021-01-15","current":6.216526,"twenty":6.149862,"median":7.785585,"eighty":11.084422,"marketCap":595350479},{"date":"2021-01-22","current":6.705707,"twenty":6.149862,"median":7.780094,"eighty":11.074992,"marketCap":642198851},{"date":"2021-01-29","current":7.180605,"twenty":6.149862,"median":7.776202,"eighty":11.068208,"marketCap":687679388},{"date":"2021-02-05","current":7.284155,"twenty":6.149862,"median":7.768418,"eighty":11.06411,"marketCap":697596196},{"date":"2021-02-12","current":6.934229,"twenty":6.163202,"median":7.760634,"eighty":11.053134,"marketCap":664084222},{"date":"2021-02-19","current":7.112763,"twenty":6.167321,"median":7.75285,"eighty":11.04396,"marketCap":681182168},{"date":"2021-02-26","current":7.202029,"twenty":6.167844,"median":7.741174,"eighty":11.038761,"marketCap":689731141},{"date":"2021-03-05","current":6.896217,"twenty":6.167844,"median":7.718575,"eighty":11.032407,"marketCap":695214499},{"date":"2021-03-12","current":7.842623,"twenty":6.167844,"median":7.698362,"eighty":11.017031,"marketCap":790622686},{"date":"2021-03-19","current":7.720506,"twenty":6.167844,"median":7.718575,"eighty":11.007626,"marketCap":778311953},{"date":"2021-03-26","current":7.411822,"twenty":6.167844,"median":7.69367,"eighty":11.00501,"marketCap":747193153},{"date":"2021-04-01","current":7.320234,"twenty":6.167844,"median":7.686686,"eighty":10.988222,"marketCap":737960103},{"date":"2021-04-09","current":7.3779,"twenty":6.167844,"median":7.67501,"eighty":10.954813,"marketCap":743773505},{"date":"2021-04-16","current":7.510194,"twenty":6.168749,"median":7.659442,"eighty":10.940212,"marketCap":757110133},{"date":"2021-04-23","current":7.364332,"twenty":6.170107,"median":7.594997,"eighty":10.930856,"marketCap":742405645},{"date":"2021-04-30","current":8.185229,"twenty":6.171613,"median":7.641929,"eighty":10.912383,"marketCap":825161134},{"date":"2021-05-07","current":9.181725,"twenty":6.178654,"median":7.67501,"eighty":10.905455,"marketCap":849502414},{"date":"2021-05-14","current":8.749253,"twenty":6.185826,"median":7.686686,"eighty":10.905455,"marketCap":809489619},{"date":"2021-05-21","current":9.203903,"twenty":6.185826,"median":7.690578,"eighty":10.897433,"marketCap":851554353},{"date":"2021-05-28","current":9.407203,"twenty":6.185826,"median":7.712361,"eighty":10.877257,"marketCap":870363786},{"date":"2021-06-04","current":9.706607,"twenty":6.189262,"median":7.720506,"eighty":10.864653,"marketCap":898064952},{"date":"2021-06-11","current":10.061456,"twenty":6.203126,"median":7.741174,"eighty":10.858681,"marketCap":930895963},{"date":"2021-06-18","current":9.603109,"twenty":6.203644,"median":7.748958,"eighty":10.836624,"marketCap":888489240},{"date":"2021-06-25","current":9.680732,"twenty":6.203808,"median":7.760634,"eighty":10.817799,"marketCap":895671024},{"date":"2021-07-02","current":9.658554,"twenty":6.203808,"median":7.768418,"eighty":10.809851,"marketCap":893619086},{"date":"2021-07-09","current":9.31849,"twenty":6.203808,"median":7.778148,"eighty":10.796921,"marketCap":862156033},{"date":"2021-07-16","current":8.963641,"twenty":6.213362,"median":7.780094,"eighty":10.785892,"marketCap":829325022},{"date":"2021-07-23","current":9.495915,"twenty":6.213362,"median":7.785616,"eighty":10.763835,"marketCap":878571539},{"date":"2021-07-30","current":9.909906,"twenty":6.216526,"median":7.795662,"eighty":10.752807,"marketCap":916874385},{"date":"2021-08-06","current":29.34912,"twenty":6.22179,"median":7.817068,"eighty":10.752807,"marketCap":823536295},{"date":"2021-08-13","current":26.023372,"twenty":6.22179,"median":7.822906,"eighty":10.813084,"marketCap":730215805},{"date":"2021-08-20","current":24.554702,"twenty":6.22179,"median":7.83069,"eighty":10.865043,"marketCap":689004931},{"date":"2021-08-27","current":24.530426,"twenty":6.22179,"median":7.834582,"eighty":10.905455,"marketCap":688323760},{"date":"2021-09-03","current":25.100901,"twenty":6.22179,"median":7.842494,"eighty":10.964493,"marketCap":704331289},{"date":"2021-09-10","current":24.275533,"twenty":6.228856,"median":7.848204,"eighty":11.013201,"marketCap":681171460},{"date":"2021-09-17","current":25.198003,"twenty":6.230622,"median":7.85015,"eighty":11.053134,"marketCap":707055975},{"date":"2021-09-24","current":24.894559,"twenty":6.230772,"median":7.876969,"eighty":11.084422,"marketCap":698541332},{"date":"2021-10-01","current":26.047647,"twenty":6.233421,"median":7.883329,"eighty":11.141011,"marketCap":730896976},{"date":"2021-10-08","current":26.897291,"twenty":6.234318,"median":7.892962,"eighty":11.19642,"marketCap":754737977},{"date":"2021-10-15","current":26.836602,"twenty":6.236185,"median":7.896854,"eighty":11.246674,"marketCap":753035049},{"date":"2021-10-22","current":28.632991,"twenty":6.237348,"median":7.914368,"eighty":11.269162,"marketCap":803441737},{"date":"2021-10-29","current":28.329547,"twenty":6.237865,"median":7.935774,"eighty":11.303569,"marketCap":794927093},{"date":"2021-11-05","current":18.151279,"twenty":6.239408,"median":7.94745,"eighty":11.328048,"marketCap":776838422},{"date":"2021-11-12","current":18.191189,"twenty":6.239772,"median":7.988112,"eighty":11.346522,"marketCap":778546510},{"date":"2021-11-19","current":18.773882,"twenty":6.239772,"median":8.014118,"eighty":11.360961,"marketCap":803484595},{"date":"2021-11-26","current":18.694061,"twenty":6.239772,"median":8.035981,"eighty":11.378852,"marketCap":800068419},{"date":"2021-12-03","current":18.103386,"twenty":6.239772,"median":8.105729,"eighty":11.403489,"marketCap":774788716},{"date":"2021-12-10","current":18.430652,"twenty":6.240495,"median":8.179783,"eighty":11.427136,"marketCap":788795038},{"date":"2021-12-17","current":18.550383,"twenty":6.243048,"median":8.213544,"eighty":11.470285,"marketCap":793919302},{"date":"2021-12-23","current":17.991637,"twenty":6.244429,"median":8.252749,"eighty":11.474686,"marketCap":770006070},{"date":"2021-12-31","current":18.749936,"twenty":6.244429,"median":8.284603,"eighty":11.575574,"marketCap":802459742},{"date":"2022-01-07","current":20.051017,"twenty":6.24581,"median":8.291955,"eighty":11.616705,"marketCap":858143411},{"date":"2022-01-14","current":21.152545,"twenty":6.248234,"median":8.320498,"eighty":11.690231,"marketCap":905286640},{"date":"2022-01-21","current":20.146802,"twenty":6.249277,"median":8.363015,"eighty":11.729858,"marketCap":862242822},{"date":"2022-01-28","current":21.392008,"twenty":6.251718,"median":8.365465,"eighty":11.776801,"marketCap":915535168},{"date":"2022-02-04","current":21.85497,"twenty":6.254157,"median":8.433466,"eighty":11.837284,"marketCap":935348988},{"date":"2022-02-11","current":21.559632,"twenty":6.257754,"median":8.47328,"eighty":11.938846,"marketCap":922709137},{"date":"2022-02-18","current":20.945011,"twenty":6.257851,"median":8.48054,"eighty":12.432666,"marketCap":896404582},{"date":"2022-02-25","current":20.529942,"twenty":6.258237,"median":8.487891,"eighty":12.775373,"marketCap":878640467},{"date":"2022-03-04","current":15.348683,"twenty":6.268592,"median":8.571294,"eighty":13.121553,"marketCap":878174885},{"date":"2022-03-11","current":15.504022,"twenty":6.275496,"median":8.601399,"eighty":13.154839,"marketCap":887062603},{"date":"2022-03-18","current":15.940166,"twenty":6.275736,"median":8.649704,"eighty":13.201441,"marketCap":912016580},{"date":"2022-03-25","current":16.890123,"twenty":6.275736,"median":8.669307,"eighty":13.248042,"marketCap":966368393},{"date":"2022-04-01","current":16.214996,"twenty":6.275736,"median":8.68891,"eighty":13.261356,"marketCap":927741004},{"date":"2022-04-08","current":16.752708,"twenty":6.275736,"median":8.726599,"eighty":13.281328,"marketCap":958506181},{"date":"2022-04-14","current":16.573471,"twenty":6.275736,"median":8.736337,"eighty":13.3013,"marketCap":948251122},{"date":"2022-04-22","current":16.011861,"twenty":6.276168,"median":8.777122,"eighty":13.329261,"marketCap":916118604},{"date":"2022-04-29","current":15.743005,"twenty":6.281175,"median":8.797306,"eighty":13.342575,"marketCap":900736015},{"date":"2022-05-06","current":9.804164,"twenty":6.2824,"median":8.848712,"eighty":13.349233,"marketCap":897659497},{"date":"2022-05-13","current":9.69216,"twenty":6.2824,"median":8.9103,"eighty":13.347901,"marketCap":887404438},{"date":"2022-05-20","current":10.270852,"twenty":6.291454,"median":8.930374,"eighty":13.347901,"marketCap":940388910},{"date":"2022-05-27","current":11.163158,"twenty":6.293718,"median":8.972794,"eighty":13.342575,"marketCap":1022087547},{"date":"2022-06-03","current":10.868211,"twenty":6.294536,"median":8.995202,"eighty":13.341244,"marketCap":995082558},{"date":"2022-06-10","current":10.244717,"twenty":6.297672,"median":9.026396,"eighty":13.341244,"marketCap":937996063},{"date":"2022-06-17","current":7.754474,"twenty":6.299555,"median":9.016925,"eighty":13.33725,"marketCap":709991918},{"date":"2022-06-24","current":8.613179,"twenty":6.299659,"median":8.99034,"eighty":13.331924,"marketCap":788614037},{"date":"2022-07-01","current":8.814788,"twenty":6.299659,"median":8.977241,"eighty":13.322603,"marketCap":807073143},{"date":"2022-07-08","current":8.900658,"twenty":6.299659,"median":8.963641,"eighty":13.313284,"marketCap":814935355},{"date":"2022-07-15","current":8.867057,"twenty":6.299659,"median":8.92485,"eighty":13.306626,"marketCap":811858837},{"date":"2022-07-22","current":9.561487,"twenty":6.300172,"median":8.963641,"eighty":13.3013,"marketCap":875440203},{"date":"2022-07-29","current":10.371656,"twenty":6.303369,"median":8.980096,"eighty":13.299969,"marketCap":949618463},{"date":"2022-08-05","current":3.850073,"twenty":6.303369,"median":8.997729,"eighty":13.29198,"marketCap":927520968},{"date":"2022-08-12","current":4.016293,"twenty":6.299659,"median":8.972794,"eighty":13.281328,"marketCap":967565231},{"date":"2022-08-19","current":3.999245,"twenty":6.293991,"median":8.937993,"eighty":13.278687,"marketCap":963458127},{"date":"2022-08-26","current":3.899797,"twenty":6.2824,"median":8.919306,"eighty":13.268103,"marketCap":939500021},{"date":"2022-09-02","current":4.077383,"twenty":6.275736,"median":8.9103,"eighty":13.268014,"marketCap":982282354},{"date":"2022-09-09","current":4.169728,"twenty":6.275496,"median":8.900658,"eighty":13.268014,"marketCap":1004529167},{"date":"2022-09-16","current":4.014873,"twenty":6.257754,"median":8.857885,"eighty":13.261356,"marketCap":967222973},{"date":"2022-09-23","current":3.607134,"twenty":6.247881,"median":8.814788,"eighty":13.254699,"marketCap":868994737},{"date":"2022-09-30","current":3.51621,"twenty":6.240977,"median":8.791187,"eighty":13.254699,"marketCap":847090183},{"date":"2022-10-07","current":3.916845,"twenty":6.239772,"median":8.777122,"eighty":13.248042,"marketCap":943607125},{"date":"2022-10-14","current":3.740679,"twenty":6.236636,"median":8.755886,"eighty":13.248042,"marketCap":901167051},{"date":"2022-10-21","current":4.087328,"twenty":6.230622,"median":8.734756,"eighty":13.241384,"marketCap":984678164},{"date":"2022-10-28","current":4.250707,"twenty":6.22179,"median":8.716798,"eighty":13.234727,"marketCap":1024037910},{"date":"2022-11-04","current":3.449288,"twenty":6.213362,"median":8.68891,"eighty":13.208098,"marketCap":1095762902},{"date":"2022-11-11","current":3.301892,"twenty":6.203808,"median":8.669307,"eighty":13.201441,"marketCap":1048938349},{"date":"2022-11-18","current":3.311575,"twenty":6.185826,"median":8.649704,"eighty":13.194783,"marketCap":1052014414},{"date":"2022-11-25","current":3.399797,"twenty":6.17312,"median":8.639313,"eighty":13.17348,"marketCap":1080040789},{"date":"2022-12-02","current":3.385811,"twenty":6.167844,"median":8.62969,"eighty":13.162828,"marketCap":1075597583},{"date":"2022-12-09","current":3.518145,"twenty":6.167844,"median":8.601399,"eighty":13.156171,"marketCap":1117637146},{"date":"2022-12-16","current":3.574091,"twenty":6.149862,"median":8.577106,"eighty":13.154839,"marketCap":1135409969},{"date":"2022-12-23","current":3.865656,"twenty":6.146266,"median":8.549709,"eighty":13.144188,"marketCap":1228033720},{"date":"2022-12-30","current":3.740853,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1188386653},{"date":"2023-01-06","current":3.441757,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1093370406},{"date":"2023-01-13","current":3.612823,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1147714231},{"date":"2023-01-20","current":3.620354,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1150106726},{"date":"2023-01-27","current":3.857048,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1225299440},{"date":"2023-02-03","current":4.130323,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1312112845},{"date":"2023-02-10","current":3.93774,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1250933319},{"date":"2023-02-17","current":3.875339,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1231109786},{"date":"2023-02-24","current":3.718259,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1181209167},{"date":"2023-03-03","current":3.363192,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1194165378},{"date":"2023-03-10","current":3.211151,"twenty":6.113691,"median":8.482899,"eighty":13.133536,"marketCap":1140180220},{"date":"2023-03-17","current":2.830086,"twenty":6.097582,"median":8.463126,"eighty":13.133536,"marketCap":1004875645},{"date":"2023-03-24","current":2.875313,"twenty":6.070129,"median":8.365465,"eighty":13.133536,"marketCap":1020934521},{"date":"2023-03-31","current":2.985014,"twenty":6.034422,"median":8.291955,"eighty":13.130873,"marketCap":1059885838},{"date":"2023-04-06","current":2.892634,"twenty":6.016569,"median":8.274802,"eighty":13.130873,"marketCap":1027084729},{"date":"2023-04-14","current":2.896483,"twenty":5.960153,"median":8.185229,"eighty":13.133536,"marketCap":1028451442},{"date":"2023-04-20","current":2.925352,"twenty":5.879004,"median":8.105729,"eighty":13.133536,"marketCap":1038701788},{"date":"2023-04-28","current":2.932088,"twenty":5.726233,"median":7.998046,"eighty":13.136199,"marketCap":1041093536},{"date":"2023-05-05","current":2.771386,"twenty":5.536171,"median":7.943558,"eighty":13.136199,"marketCap":984033273},{"date":"2023-05-12","current":2.975648,"twenty":5.442294,"median":7.932539,"eighty":13.136199,"marketCap":1050433502},{"date":"2023-05-19","current":3.089052,"twenty":5.341054,"median":7.932539,"eighty":13.136199,"marketCap":1090466310},{"date":"2023-05-26","current":2.874844,"twenty":5.253436,"median":7.932539,"eighty":13.136199,"marketCap":1014848784},{"date":"2023-06-02","current":2.846736,"twenty":5.130475,"median":7.932539,"eighty":13.136199,"marketCap":1004926122},{"date":"2023-06-09","current":3.07839,"twenty":5.004569,"median":7.932539,"eighty":13.136199,"marketCap":1086702542},{"date":"2023-06-16","current":3.058036,"twenty":4.918423,"median":7.932539,"eighty":13.136199,"marketCap":1079517166},{"date":"2023-06-23","current":2.916523,"twenty":4.864674,"median":7.935774,"eighty":13.138862,"marketCap":1029561696},{"date":"2023-06-30","current":2.952386,"twenty":4.815342,"median":7.93772,"eighty":13.141525,"marketCap":1042221644},{"date":"2023-07-07","current":2.944631,"twenty":4.771165,"median":7.93772,"eighty":13.141525,"marketCap":1039484358},{"date":"2023-07-14","current":3.066759,"twenty":4.749076,"median":7.93772,"eighty":13.141525,"marketCap":1082596613},{"date":"2023-07-21","current":3.116192,"twenty":4.697536,"median":7.93772,"eighty":13.141525,"marketCap":1100046811},{"date":"2023-07-28","current":3.215057,"twenty":4.671766,"median":7.93772,"eighty":13.141525,"marketCap":1134947207},{"date":"2023-08-04","current":3.279998,"twenty":4.616544,"median":7.93772,"eighty":13.141525,"marketCap":1157871978},{"date":"2023-08-11","current":4.645552,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075069076},{"date":"2023-08-18","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-08-25","current":4.663295,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1079175005},{"date":"2023-09-01","current":4.624853,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1070278826},{"date":"2023-09-08","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-09-15","current":4.775663,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1105179222},{"date":"2023-09-22","current":4.867332,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1126393189},{"date":"2023-09-29","current":5.173389,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1197220464},{"date":"2023-10-06","current":4.475521,"twenty":4.542915,"median":7.93772,"eighty":13.141525,"marketCap":1035720590},{"date":"2023-10-13","current":4.511006,"twenty":4.484012,"median":7.93772,"eighty":13.141525,"marketCap":1043932448},{"date":"2023-10-20","current":4.482914,"twenty":4.482914,"median":7.93772,"eighty":13.141525,"marketCap":1037431394},{"date":"2023-10-27","current":4.534662,"twenty":4.467537,"median":7.94745,"eighty":13.149513,"marketCap":1049407020},{"date":"2023-11-03","current":4.904296,"twenty":4.458666,"median":7.94745,"eighty":13.149513,"marketCap":1134947207},{"date":"2023-11-10","current":7.439549,"twenty":4.458666,"median":7.935774,"eighty":13.149513,"marketCap":1088071185},{"date":"2023-11-17","current":7.820894,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1143844827},{"date":"2023-11-24","current":7.993518,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1169092039},{"date":"2023-12-01","current":8.460278,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1237357955},{"date":"2023-12-08","current":8.743603,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1278795691},{"date":"2023-12-15","current":8.690189,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1270983658},{"date":"2023-12-22","current":9.616802,"twenty":4.459848,"median":7.934448,"eighty":13.146851,"marketCap":1406505433},{"date":"2023-12-29","current":9.686473,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1416695040},{"date":"2024-01-05","current":9.75382,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1426544994},{"date":"2024-01-12","current":9.809556,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1434696679},{"date":"2024-01-19","current":10.16023,"twenty":4.448612,"median":7.939666,"eighty":13.154839,"marketCap":1485984368},{"date":"2024-01-26","current":10.740814,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1570897761},{"date":"2024-02-02","current":10.601474,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1550518547},{"date":"2024-02-09","current":10.963759,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1603504503},{"date":"2024-02-16","current":11.124,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1626940600},{"date":"2024-02-23","current":10.647921,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1557311618},{"date":"2024-03-01","current":11.10678,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1583804596},{"date":"2024-03-08","current":11.32675,"twenty":4.4563,"median":7.94745,"eighty":13.154839,"marketCap":1615171958},{"date":"2024-03-15","current":10.799262,"twenty":4.4563,"median":7.990262,"eighty":13.154839,"marketCap":1539953125},{"date":"2024-03-22","current":11.659401,"twenty":4.4563,"median":8.049544,"eighty":13.154839,"marketCap":1662607257},{"date":"2024-03-28","current":10.571159,"twenty":4.4563,"median":8.239503,"eighty":13.154839,"marketCap":1507426062},{"date":"2024-04-05","current":10.811142,"twenty":4.452456,"median":8.461702,"eighty":13.154839,"marketCap":1541647243},{"date":"2024-04-12","current":11.186562,"twenty":4.452456,"median":8.566313,"eighty":13.154839,"marketCap":1595181367},{"date":"2024-04-19","current":10.81827,"twenty":4.452456,"median":8.624771,"eighty":13.154839,"marketCap":1542663714},{"date":"2024-04-26","current":11.245964,"twenty":4.4563,"median":8.639313,"eighty":13.154839,"marketCap":1603651956},{"date":"2024-05-03","current":11.324374,"twenty":4.4563,"median":8.690189,"eighty":13.154839,"marketCap":1614833134},{"date":"2024-05-10","current":14.682959,"twenty":4.4563,"median":8.734756,"eighty":13.168154,"marketCap":1565364893},{"date":"2024-05-17","current":13.78037,"twenty":4.4563,"median":8.734756,"eighty":13.224197,"marketCap":1469138999},{"date":"2024-05-24","current":14.166489,"twenty":4.4563,"median":8.734756,"eighty":13.241384,"marketCap":1510303519},{"date":"2024-05-31","current":15.403069,"twenty":4.4563,"median":8.734756,"eighty":13.248042,"marketCap":1642136538},{"date":"2024-06-07","current":15.399881,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1641796762},{"date":"2024-06-14","current":15.042931,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1603741870},{"date":"2024-06-21","current":14.389583,"twenty":4.452456,"median":8.72747,"eighty":13.257384,"marketCap":1534087827},{"date":"2024-06-28","current":14.542562,"twenty":4.452456,"median":8.72747,"eighty":13.270766,"marketCap":1550397066},{"date":"2024-07-05","current":14.395957,"twenty":4.452456,"median":8.72747,"eighty":13.285322,"marketCap":1534767378},{"date":"2024-07-12","current":13.586443,"twenty":4.452456,"median":8.72747,"eighty":13.285322,"marketCap":1448464320},{"date":"2024-07-19","current":12.767369,"twenty":4.452456,"median":8.72747,"eighty":13.228966,"marketCap":1361141934},{"date":"2024-07-26","current":12.910786,"twenty":4.452456,"median":8.72747,"eighty":13.052045,"marketCap":1376431846},{"date":"2024-08-02","current":13.302795,"twenty":4.452456,"median":8.72747,"eighty":12.924809,"marketCap":1418224272},{"date":"2024-08-09","current":12.449802,"twenty":4.452456,"median":8.72747,"eighty":12.75462,"marketCap":1335540014},{"date":"2024-08-16","current":13.196601,"twenty":4.452456,"median":8.72747,"eighty":12.789678,"marketCap":1415652134},{"date":"2024-08-23","current":13.473893,"twenty":4.452456,"median":8.72747,"eighty":13.02799,"marketCap":1445398406},{"date":"2024-08-30","current":14.204937,"twenty":4.452456,"median":8.72747,"eighty":13.191559,"marketCap":1523820396},{"date":"2024-09-06","current":13.316341,"twenty":4.452456,"median":8.72747,"eighty":13.222287,"marketCap":1428497115},{"date":"2024-09-13","current":13.558971,"twenty":4.452456,"median":8.72747,"eighty":13.305504,"marketCap":1454525103},{"date":"2024-09-20","current":14.226994,"twenty":4.452456,"median":8.72747,"eighty":13.395117,"marketCap":1526186577},{"date":"2024-09-27","current":14.085197,"twenty":4.452456,"median":8.72747,"eighty":13.544476,"marketCap":1510975415},{"date":"2024-10-04","current":14.976944,"twenty":4.452456,"median":8.72747,"eighty":13.679972,"marketCap":1606636722},{"date":"2024-10-11","current":14.803637,"twenty":4.452456,"median":8.72747,"eighty":13.85562,"marketCap":1588045302},{"date":"2024-10-18","current":14.529495,"twenty":4.452456,"median":8.72747,"eighty":14.019655,"marketCap":1558637056},{"date":"2024-10-25","current":14.772126,"twenty":4.452456,"median":8.72747,"eighty":14.168401,"marketCap":1584665044},{"date":"2024-11-01","current":14.778428,"twenty":4.452456,"median":8.72747,"eighty":14.27768,"marketCap":1585341095},{"date":"2024-11-08","current":13.141823,"twenty":4.452456,"median":8.73918,"eighty":14.377354,"marketCap":1640493731},{"date":"2024-11-15","current":13.379586,"twenty":4.452456,"median":8.78252,"eighty":14.377354,"marketCap":1670173717},{"date":"2024-11-22","current":14.322533,"twenty":4.452456,"median":8.81344,"eighty":14.377354,"marketCap":1787881840},{"date":"2024-11-29","current":15.251971,"twenty":4.452456,"median":8.883858,"eighty":14.399781,"marketCap":1903903601},{"date":"2024-12-06","current":15.273586,"twenty":4.452456,"median":8.934183,"eighty":14.482822,"marketCap":1906601781},{"date":"2024-12-13","current":14.4198,"twenty":4.452456,"median":9.012663,"eighty":14.537463,"marketCap":1800023652},{"date":"2024-12-20","current":12.93378,"twenty":4.452456,"median":9.090449,"eighty":14.537463,"marketCap":1614523744},{"date":"2024-12-27","current":12.995923,"twenty":4.452456,"median":9.19602,"eighty":14.537463,"marketCap":1622281013},{"date":"2025-01-03","current":12.766265,"twenty":4.452456,"median":9.268408,"eighty":14.537463,"marketCap":1593612846},{"date":"2025-01-10","current":12.631172,"twenty":4.448612,"median":9.31881,"eighty":14.538738,"marketCap":1576749218},{"date":"2025-01-17","current":14.282006,"twenty":4.448612,"median":9.382279,"eighty":14.538738,"marketCap":1782822752},{"date":"2025-01-24","current":13.892938,"twenty":4.448612,"median":9.455255,"eighty":14.538738,"marketCap":1734255503},{"date":"2025-01-31","current":14.63865,"twenty":4.448612,"median":9.481129,"eighty":14.558635,"marketCap":1827342730},{"date":"2025-02-07","current":15.684268,"twenty":4.448612,"median":9.514397,"eighty":14.63454,"marketCap":1957867210},{"date":"2025-02-14","current":15.462716,"twenty":4.448612,"median":9.568033,"eighty":14.675959,"marketCap":1930210860},{"date":"2025-02-21","current":15.732902,"twenty":4.448612,"median":9.580931,"eighty":14.694621,"marketCap":1963938116},{"date":"2025-02-28","current":20.937616,"twenty":4.448612,"median":9.626092,"eighty":14.774647,"marketCap":1933567942},{"date":"2025-03-07","current":19.49754,"twenty":4.444767,"median":9.675026,"eighty":14.838928,"marketCap":1800578330},{"date":"2025-03-14","current":19.960552,"twenty":4.444767,"median":9.675026,"eighty":14.901539,"marketCap":1843337016},{"date":"2025-03-21","current":19.362647,"twenty":4.444767,"median":9.689317,"eighty":15.017908,"marketCap":1788121076},{"date":"2025-03-28","current":19.698057,"twenty":4.444767,"median":9.708699,"eighty":15.110765,"marketCap":1819095871},{"date":"2025-04-04","current":17.87153,"twenty":4.444767,"median":9.75606,"eighty":15.125044,"marketCap":1650417909},{"date":"2025-04-11","current":17.576223,"twenty":4.448612,"median":9.799015,"eighty":15.243459,"marketCap":1623146621},{"date":"2025-04-17","current":18.509538,"twenty":4.448612,"median":9.802712,"eighty":15.283315,"marketCap":1709337357},{"date":"2025-04-25","current":18.910572,"twenty":4.444767,"median":9.80686,"eighty":15.360398,"marketCap":1746372438},{"date":"2025-05-02","current":18.710055,"twenty":4.444767,"median":9.80686,"eighty":15.401794,"marketCap":1727854897},{"date":"2025-05-09","current":14.05872,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1621799891},{"date":"2025-05-16","current":14.406029,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1661865116},{"date":"2025-05-23","current":14.373925,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1658161608},{"date":"2025-05-30","current":15.450609,"twenty":4.444767,"median":9.80686,"eighty":15.444645,"marketCap":1782366767},{"date":"2025-06-06","current":15.621074,"twenty":4.444767,"median":9.80686,"eighty":15.514776,"marketCap":1802031456},{"date":"2025-06-13","current":16.520424,"twenty":4.444767,"median":9.80686,"eighty":15.572999,"marketCap":1905779645},{"date":"2025-06-20","current":16.170677,"twenty":4.440923,"median":9.804164,"eighty":15.627805,"marketCap":1865433127},{"date":"2025-06-27","current":15.57111,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1796267668},{"date":"2025-07-03","current":15.479999,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1785757230},{"date":"2025-07-11","current":15.432974,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1780332488},{"date":"2025-07-18","current":14.992116,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1729475533},{"date":"2025-07-22","current":15.021507,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1732865997}],"updateTime":1753262218082}}}